OpenURL Connection Search

Select item for more details and to access through your institution.

Defective DNA repair in hereditary ovarian cancers: Implications for therapy.
Published in:
American Journal of Health-System Pharmacy, 2018, v. 75, n. 21, p. 1697, doi. 10.2146/ajhp180124
By:
- Burgess, Brian T.;
- Kolesar, Jill M.
Publication type:
Article
Clinical Factors Associated with Longer Hospital Stay Following Ovarian Cancer Surgery.
Published in:
Healthcare (2227-9032), 2019, v. 7, n. 3, p. 85, doi. 10.3390/healthcare7030085
By:
- Smith, Christopher G.;
- Davenport, Daniel L.;
- Gorski, Justin;
- McDowell, Anthony;
- Burgess, Brian T.;
- Fredericks, Tricia I.;
- Baldwin, Lauren A.;
- Miller, Rachel W.;
- DeSimone, Christopher P.;
- Dietrich III, Charles S.;
- Gallion, Holly H.;
- Pavlik, Edward J.;
- van Nagell, John R.;
- Ueland, Frederick R.
Publication type:
Article
Olaparib Combined with an ATR or Chk1 Inhibitor as a Treatment Strategy for Acquired Olaparib-Resistant BRCA1 Mutant Ovarian Cells.
Published in:
Diagnostics (2075-4418), 2020, v. 10, n. 2, p. 121, doi. 10.3390/diagnostics10020121
By:
- Burgess, Brian T.;
- Anderson, Abigail M.;
- McCorkle, J. Robert;
- Wu, Jianrong;
- Ueland, Frederick R.;
- Kolesar, Jill M.
Publication type:
Article
Disease-Specific Survival of Type I and Type II Epithelial Ovarian Cancers—Stage Challenges Categorical Assignments of Indolence & Aggressiveness.
Published in:
Diagnostics (2075-4418), 2020, v. 10, n. 2, p. 56, doi. 10.3390/diagnostics10020056
By:
- Pavlik, Edward J.;
- Smith, Christopher;
- Dennis, Taylor S.;
- Harvey, Elizabeth;
- Huang, Bin;
- Chen, Quan;
- West Piecoro, Dava;
- Burgess, Brian T.;
- McDowell, Anthony;
- Gorski, Justin;
- Baldwin, Lauren A.;
- Miller, Rachel W.;
- DeSimone, Christopher P.;
- Dietrich III, Charles;
- Gallion, Holly H.;
- Ueland, Frederick R.;
- van Nagell, John R.
Publication type:
Article

Found: 4

Defective DNA repair in hereditary ovarian cancers: Implications for therapy.

Clinical Factors Associated with Longer Hospital Stay Following Ovarian Cancer Surgery.

Olaparib Combined with an ATR or Chk1 Inhibitor as a Treatment Strategy for Acquired Olaparib-Resistant BRCA1 Mutant Ovarian Cells.

Disease-Specific Survival of Type I and Type II Epithelial Ovarian Cancers—Stage Challenges Categorical Assignments of Indolence & Aggressiveness.